Profile data is unavailable for this security.
About the company
AVROBIO, Inc. is a gene therapy company. The Company is focused on developing potentially curative hematopoietic stem cells (HSC) gene therapies to treat patients with rare diseases following a single dose treatment regimen. The gene therapies that the Company is engaged in developing employ HSCs that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The Company's development focus has been on a group of rare genetic diseases referred to as lysosomal disorders, primarily managed with enzyme replacement therapies (ERTs). Its pipeline is comprised of three HSC gene therapy programs, which include AVR-RD-02 for the treatment of Gaucher disease type 1 and type 3; AVR-RD-03 for the treatment of Pompe disease, and AVR-RD-01 for the treatment of Fabry disease.
- Revenue in USD (TTM)0.00
- Net income in USD30.31m
- Incorporated2015
- Employees13.00
- LocationAVROBIO IncOne Broadway, 14Th FloorCAMBRIDGE 02142United StatesUSA
- Phone+1 (617) 914-8420
- Fax+1 (302) 655-5049
- Websitehttps://www.avrobio.com/
More ▼
Mergers & acquisitions
| Acquired company | AVRO:NSQ since announced | Transaction value |
|---|---|---|
| Tectonic Therapeutic Inc | 4.38% | -- |
Data delayed at least 15 minutes, as of Jun 14 2024 21:00 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Regencell Bioscience Holdings Ltd | 0.00 | -7.45m | 62.07m | 12.00 | -- | 3.64 | -- | -- | -0.5863 | -0.5863 | 0.00 | 1.31 | 0.00 | -- | -- | 0.00 | -82.73 | -- | -113.11 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 21.15 | -- | -- | -- |
| Turnstone Biologics Corp | 0.00 | -74.92m | 62.45m | 82.00 | -- | 0.7805 | -- | -- | -3.53 | -3.53 | 0.00 | 3.46 | 0.00 | -- | -- | 0.00 | -80.25 | -- | -94.45 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -73.66 | -- | -78.05 | -- | -- | -- |
| RetinalGenix Technologies Inc | 0.00 | -3.73m | 62.51m | 0.00 | -- | -- | -- | -- | -0.2124 | -0.2124 | 0.00 | -0.085 | 0.00 | -- | -- | -- | -12,800.17 | -9,163.75 | -- | -- | -- | -- | -- | -- | -- | -969.35 | -- | -- | -- | -- | 46.58 | -- | -- | -- |
| vTv Therapeutics Inc | 1.00m | -20.62m | 63.27m | 16.00 | -- | 3.04 | -- | 63.27 | -8.76 | -8.76 | 0.383 | 6.91 | 0.0241 | -- | 2.04 | 62,500.00 | -63.15 | -111.84 | -128.59 | -- | -- | -- | -2,621.10 | -680.94 | -- | -- | 0.00 | -- | -100.00 | -- | -5.67 | -- | -- | -- |
| enVVeno Medical Corp | 0.00 | -22.12m | 63.58m | 31.00 | -- | 1.50 | -- | -- | -1.70 | -1.70 | 0.00 | 3.18 | 0.00 | -- | -- | 0.00 | -54.31 | -58.43 | -56.14 | -62.76 | -- | -- | -- | -260,799.30 | -- | -- | 0.00 | -- | -- | -- | 4.67 | -- | 21.58 | -- |
| Rallybio Corp | 0.00 | -76.28m | 64.04m | 43.00 | -- | 0.6552 | -- | -- | -1.88 | -1.88 | 0.00 | 2.36 | 0.00 | -- | -- | 0.00 | -58.30 | -- | -62.32 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.87 | -- | -- | -- |
| Avrobio Inc | 0.00 | 30.31m | 64.20m | 13.00 | 2.07 | 0.7224 | 2.10 | -- | 0.6903 | 0.6903 | 0.00 | 1.98 | 0.00 | -- | -- | 0.00 | 34.57 | -45.22 | 38.47 | -49.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 111.48 | -- | -66.27 | -- |
| Tempest Therapeutics Inc | 0.00 | -29.76m | 64.43m | 17.00 | -- | 3.12 | -- | -- | -1.76 | -1.76 | 0.00 | 0.9287 | 0.00 | -- | -- | 0.00 | -72.84 | -57.10 | -93.72 | -71.20 | -- | -- | -- | -- | -- | -141.39 | 0.3394 | -- | -- | -- | 17.41 | -- | 36.40 | -- |
| Passage Bio Inc | 0.00 | -84.44m | 64.72m | 58.00 | -- | 0.6168 | -- | -- | -1.53 | -1.53 | 0.00 | 1.70 | 0.00 | -- | -- | 0.00 | -47.73 | -48.56 | -52.17 | -52.09 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 25.02 | -- | -43.53 | -- |
| AN2 Therapeutics Inc | 0.00 | -66.03m | 64.73m | 41.00 | -- | 0.585 | -- | -- | -2.59 | -2.59 | 0.00 | 3.71 | 0.00 | -- | -- | 0.00 | -62.19 | -- | -68.38 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -51.33 | -- | -- | -- |
| Bioqual Inc | 62.86m | 957.02k | 64.85m | 108.00 | 67.76 | 1.67 | 18.49 | 1.03 | 1.07 | 1.07 | 70.28 | 43.41 | 1.04 | -- | 2.99 | -- | 1.59 | 8.14 | 1.80 | 9.52 | 14.13 | 19.36 | 1.52 | 7.13 | -- | -- | 0.00 | 21.43 | -5.27 | 11.79 | -84.12 | -25.26 | 1.60 | 10.76 |
| Kronos Bio Inc | 7.59m | -116.39m | 64.90m | 61.00 | -- | 0.4738 | -- | 8.55 | -2.00 | -2.00 | 0.1301 | 2.28 | 0.0322 | -- | -- | 122,371.00 | -49.32 | -35.47 | -54.43 | -37.14 | -- | -- | -1,534.11 | -7,975.76 | -- | -- | 0.00 | -- | -- | -- | 15.41 | -- | -8.78 | -- |
| Medicinova Inc | 1.00m | -8.41m | 65.23m | 13.00 | -- | 1.09 | -- | 65.23 | -0.1714 | -0.1714 | 0.0204 | 1.22 | 0.0149 | -- | -- | 76,923.08 | -12.55 | -15.36 | -13.06 | -15.90 | -- | -- | -840.85 | -1,182.54 | -- | -- | 0.00 | -- | -- | -- | 39.08 | -- | 15.87 | -- |
| Annovis Bio Inc | 0.00 | -47.53m | 65.35m | 6.00 | -- | -- | -- | -- | -5.04 | -5.04 | 0.00 | -0.3046 | 0.00 | -- | -- | 0.00 | -284.97 | -106.31 | -411.92 | -124.71 | -- | -- | -- | -- | -- | -9.20 | -- | -- | -- | -- | -121.90 | -- | -- | -- |
| Cue Biopharma Inc | 7.02m | -49.97m | 66.15m | 53.00 | -- | 2.20 | -- | 9.42 | -1.07 | -1.07 | 0.1495 | 0.6175 | 0.1035 | -- | 8.80 | 132,452.80 | -73.69 | -57.45 | -96.35 | -68.41 | -- | -- | -711.84 | -810.87 | -- | -- | 0.1935 | -- | 340.88 | 36.88 | 4.30 | -- | -- | -- |
| Provectus Biopharmaceuticals Inc | 590.75k | -2.78m | 66.70m | 4.00 | -- | -- | -- | 112.91 | -0.0066 | -0.0066 | 0.0014 | -0.0178 | 0.4221 | -- | 1,358.05 | 147,687.50 | -198.50 | -276.33 | -- | -- | -- | -- | -470.31 | -1,667.76 | -- | -10.24 | -- | -- | -43.61 | -- | 12.74 | -- | -- | -- |
Data as of Jun 14 2024. Currency figures normalised to AVROBIO Inc's reporting currency: US Dollar USD
43.75%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BML Capital Management LLCas of 14 May 2024 | 4.77m | 10.62% |
| Adar1 Capital Management LLCas of 31 Mar 2024 | 3.95m | 8.81% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 2.02m | 4.49% |
| Verition Fund Management LLCas of 31 Mar 2024 | 1.93m | 4.29% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 1.87m | 4.16% |
| Acadian Asset Management LLCas of 31 Mar 2024 | 1.24m | 2.76% |
| Newtyn Management LLCas of 31 Mar 2024 | 1.12m | 2.49% |
| Aisling Capital Management LPas of 31 Mar 2024 | 1.01m | 2.25% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 888.17k | 1.98% |
| Tang Capital Management LLCas of 31 Mar 2024 | 852.80k | 1.90% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
